Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.55 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.46 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3981568 | 1.00 | HDAC1 (0.55) | HDAC1HDAC2MAOAMAOB | |
| SCHEMBL9154485 | 0.98 | HDAC1 (0.57) | HDAC1HDAC2MAOAMAOB | |
| SCHEMBL10723135 | 0.98 | HDAC1 (0.57) | HDAC1HDAC2MAOAMAOB | |
| SCHEMBL9154475 | 0.98 | HDAC1 (0.57) | HDAC1HDAC2MAOAMAOB | |
| SCHEMBL8574266 | 0.77 | HDAC1 (0.59) | HDAC1HDAC2MAOAMAOB | |
| SCHEMBL11207094 | 0.77 | HDAC1 (0.55) | HDAC1HDAC2MAOAMAOB | |
| Hydrochloric Acid SCHEMBL11708050 | 0.77 | HDAC1 (0.53) | HDAC1HDAC2MAOAMAOB | |
| Hydrochloric Acid SCHEMBL11708055 | 0.77 | HDAC1 (0.53) | HDAC1HDAC2MAOAMAOB | |
| SCHEMBL2291836 | 0.76 | ATM (0.45) | HDAC1HDAC2MAOAMAOB | |
| SCHEMBL16787362 | 0.76 | ATM (0.45) | HDAC1HDAC2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| US-20190076406-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-03-14 | — | — | US | disclosed |
| US-20180360808-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | Benevolentai Cambridge Limited (GB) | 2018-12-20 | — | — | US | disclosed |
| EP-3386494-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | Benevolentai Cambridge Limited (GB) | 2018-10-17 | — | — | EP | disclosed |
| US-20180000791-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2017098236-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| US-20160279104-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-09-29 | — | — | US | disclosed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | PROXIMAGEN LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20140170160-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2014-06-19 | — | — | US | disclosed |
| US-8636995-B2 | Methods and devices to regulate stem cell homing | CARDIAC PACEMAKERS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120276111-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-11-01 | — | — | US | disclosed |
| US-20090170770-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP 1) INHIBITOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-07-02 | — | — | US | disclosed |
| WO-2009061830-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20080057027-A1 | METHODS AND DEVICES TO REGULATE STEM CELL HOMING | CARDIAC PACEMAKERS, INC (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058922-A1 | METHODS AND DEVICES EMPLOYING VAP-1 INHIBITORS | CARDIAC PACEMAKERS, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| EP-0067105-B1 | ALLYL AMINE MAO INHIBITORS | MERRELL DOW FRANCE ET CIE (FR) | 1987-09-23 | — | — | EP | disclosed |
| US-4454158-A | Allyl amine MAO inhibitors | MERRELL TORAUDE ET COMPAGNIE (FR) | 1984-06-12 | — | — | US | disclosed |
| EP-0067105-A2 | Allyl amine MAO inhibitors | MERRELL DOW FRANCE ET CIE (FR) | 1982-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140170160-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | VCAM1, VAPB, VAPA | HDAC1 1426/4885HDAC2 3037/4885MAOA 1932/4885 |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | HDAC1 1927/4885HDAC2 3989/4885MAOA 563/4885 |
| US-20180360808-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | HDAC1 1927/4885HDAC2 3989/4885MAOA 563/4885 |
| US-20160279104-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | VCAM1, VAPB, VAPA | HDAC1 1426/4885HDAC2 3037/4885MAOA 1932/4885 |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, AOX1 | HDAC1 1518/4885HDAC2 2297/4885MAOA 83/4885 |
| US-20120276111-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | VCAM1, VAPB, VAPA | HDAC1 1426/4885HDAC2 3037/4885MAOA 1932/4885 |
| US-20190076406-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | VCAM1, VAPB, VAPA | HDAC1 1426/4885HDAC2 3037/4885MAOA 1932/4885 |
| US-20180000791-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | VCAM1, VAPB, VAPA | HDAC1 1426/4885HDAC2 3037/4885MAOA 1932/4885 |
| US-20090170770-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP 1) INHIBITOR | VCAM1, VAPB, FLT1 | HDAC1 1368/4885HDAC2 3012/4885MAOA 1807/4885 |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | VAPB, VAPA, AOX1 | HDAC1 1582/4885HDAC2 2461/4885MAOA 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.